1. This study evaluated the abuse potential of pitolisant, a selective H3-receptor antagonist/inverse agonist recently approved by the US Food and Drug Administration for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
2. The study found that pitolisant had significantly lower potential for abuse compared to phentermine and an overall profile similar to placebo, suggesting a low risk of abuse for pitolisant.
3. Adverse events were reported in 82.1% of participants after taking phentermine HCl 60 mg, 72.5% after taking pitolisant 213.6 mg, 47.5% after taking pitolisant 35.6 mg, and 48.8% after taking placebo administration.
The article is generally reliable and trustworthy as it provides evidence from a clinical trial conducted to evaluate the human abuse potential of pitolisant in healthy, nondependent recreational stimulant users using a double-blind crossover design with 38 study completers (73.7% male; 65.8% white; mean age, 33.3 years). The primary endpoint was maximum effect (Emax) on the 100-point Drug Liking (“at this moment”) visual analog scale which showed that mean Drug Liking Emax was significantly greater for phentermine versus pitolisant 35.6 mg (mean difference, 21.4; p < 0.0001) and pitolisant 213.6 mg (mean difference, 19.7; p < 0